Crizotinib, an ATP-competitive aminopyridine inhibits tyrosine phosphorylation of ALK with an IC50 of 20-40 nM and response in 57% of patients with ALK-rearrangement positive lung cancer.5 Here, ALK is linked to lung cancer.